IF 1 Q4 PHARMACOLOGY & PHARMACY
Duncan Long BPharm, Jonathon Beck BPharm, Nazanin Falconer BPharm, PhD, Salih Salih MBCHB, MBH, FRACP
{"title":"A retrospective study of duloxetine for phantom limb pain post lower-limb amputation","authors":"Duncan Long BPharm,&nbsp;Jonathon Beck BPharm,&nbsp;Nazanin Falconer BPharm, PhD,&nbsp;Salih Salih MBCHB, MBH, FRACP","doi":"10.1002/jppr.1937","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Phantom limb pain (PLP) refers to the painful sensory perception of a missing limb after amputation, which can have physical and psychological impacts.</p>\n </section>\n \n <section>\n \n <h3> Aim</h3>\n \n <p>To determine the effectiveness of duloxetine for pain management in PLP by the reduction of opioid doses and other neuropathic analgesics when introduced into multimodal pain management strategies in the subacute rehabilitation setting.</p>\n </section>\n \n <section>\n \n <h3> Method</h3>\n \n <p>This was a retrospective observational case-matched cohort study of patients who were admitted to a geriatric and rehabilitation unit at a tertiary Australian hospital from January 2005–December 2017 with PLP after lower-limb amputation. Patients were included if they had a new amputation and experienced PLP. The primary outcome was a difference in oxycodone dose equivalents at discharge between the two cohorts. Univariable analysis was used to compare groups. Ethical approval was granted by the Metro South Low Negligible Risk Ethics Committee (Reference no: LNR/2018/QMS/47370) and the study conforms with the <i>National statement on ethical conduct in human research</i>.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Thirty patients from the duloxetine treatment cohort and 57 patients from the non-duloxetine cohort were identified. Participants were predominantly male (81%) and had a median age of 63 years (interquartile range = 10.7). Both populations showed a similar rate of opioid dose reduction comparing doses at admission with those at discharge. There were no significant differences in absolute oxycodone equivalent doses at the two observed check points: admission and discharge.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This study demonstrated that opioid consumption in post-surgical lower-limb amputees reporting PLP was not significantly different between populations that used and did not use duloxetine. Future research should evaluate the efficacy of duloxetine in PLP pain management using a multisite prospective study design.</p>\n </section>\n </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"55 1","pages":"46-52"},"PeriodicalIF":1.0000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1937","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy Practice and Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jppr.1937","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景 幻肢痛(PLP)是指截肢后对缺失肢体的疼痛感觉,会对患者的身体和心理造成影响。 目的 通过在亚急性康复环境中采用多模式疼痛管理策略,减少阿片类药物和其他神经病理性镇痛药的剂量,确定度洛西汀对幻肢痛的疼痛管理效果。 方法 这是一项回顾性观察病例匹配队列研究,研究对象为 2005 年 1 月至 2017 年 12 月期间入住澳大利亚一家三级医院老年病与康复科的下肢截肢后 PLP 患者。新截肢并经历过PLP的患者均被纳入研究范围。主要结果是两组患者出院时羟考酮剂量当量的差异。采用单变量分析对两组进行比较。该研究获得了大都会南部低轻微风险伦理委员会的伦理批准(参考编号:LNR/2018/QMS/47370),并符合国家人类研究伦理行为声明。 结果 从度洛西汀治疗队列中确定了 30 名患者,从非度洛西汀队列中确定了 57 名患者。参与者主要为男性(81%),中位年龄为 63 岁(四分位数间距 = 10.7)。入院时与出院时的阿片类药物剂量比较显示,两种人群的阿片类药物剂量减少率相似。入院和出院这两个观察点的羟考酮绝对当量剂量没有明显差异。 结论 本研究表明,在使用和未使用度洛西汀的人群中,手术后下肢截肢者报告 PLP 时的阿片类药物消耗量没有明显差异。今后的研究应采用多地点前瞻性研究设计,评估度洛西汀在 PLP 疼痛治疗中的疗效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A retrospective study of duloxetine for phantom limb pain post lower-limb amputation

Background

Phantom limb pain (PLP) refers to the painful sensory perception of a missing limb after amputation, which can have physical and psychological impacts.

Aim

To determine the effectiveness of duloxetine for pain management in PLP by the reduction of opioid doses and other neuropathic analgesics when introduced into multimodal pain management strategies in the subacute rehabilitation setting.

Method

This was a retrospective observational case-matched cohort study of patients who were admitted to a geriatric and rehabilitation unit at a tertiary Australian hospital from January 2005–December 2017 with PLP after lower-limb amputation. Patients were included if they had a new amputation and experienced PLP. The primary outcome was a difference in oxycodone dose equivalents at discharge between the two cohorts. Univariable analysis was used to compare groups. Ethical approval was granted by the Metro South Low Negligible Risk Ethics Committee (Reference no: LNR/2018/QMS/47370) and the study conforms with the National statement on ethical conduct in human research.

Results

Thirty patients from the duloxetine treatment cohort and 57 patients from the non-duloxetine cohort were identified. Participants were predominantly male (81%) and had a median age of 63 years (interquartile range = 10.7). Both populations showed a similar rate of opioid dose reduction comparing doses at admission with those at discharge. There were no significant differences in absolute oxycodone equivalent doses at the two observed check points: admission and discharge.

Conclusion

This study demonstrated that opioid consumption in post-surgical lower-limb amputees reporting PLP was not significantly different between populations that used and did not use duloxetine. Future research should evaluate the efficacy of duloxetine in PLP pain management using a multisite prospective study design.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Pharmacy Practice and Research
Journal of Pharmacy Practice and Research Health Professions-Pharmacy
CiteScore
1.60
自引率
9.50%
发文量
68
期刊介绍: The purpose of this document is to describe the structure, function and operations of the Journal of Pharmacy Practice and Research, the official journal of the Society of Hospital Pharmacists of Australia (SHPA). It is owned, published by and copyrighted to SHPA. However, the Journal is to some extent unique within SHPA in that it ‘…has complete editorial freedom in terms of content and is not under the direction of the Society or its Council in such matters…’. This statement, originally based on a Role Statement for the Editor-in-Chief 1993, is also based on the definition of ‘editorial independence’ from the World Association of Medical Editors and adopted by the International Committee of Medical Journal Editors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信